Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial
(NASDAQ: APVO) Delayed: 1.81 -0.03 (1.63%)
Previous Close $1.84    52 Week High $4.33 
Open $1.84    52 Week Low $1.80 
Day High $1.89    P/E N/A 
Day Low $1.80    EPS $0.00 
Volume 22,430